EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

YB-1 Is a Novel Target for the Inhibition of α-Adrenergic-Induced Hypertrophy

Jacqueline Heger, Stefan Partsch, Claudia Harjung, Zoltán V Varga iD, Tamás Baranyai, Johannes Weiß, Lea Kremer, Fabian Locquet, Przemyslaw Leszek, Bence Ágg iD, Bettina Benczik iD, Péter Ferdinandy und 2 weitere

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms25010401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Jacqueline Heger und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Physiology, Justus Liebig University, 35392 Giessen, Germany. Hauptthemen laut MEDLINE: Adrenergic Agents, Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovation Fund of Hungary, European Union's Horizon 2020 research and innovation programme, the National Research, Development and Innovation Fund of Hungary.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac hypertrophy resulting from sympathetic nervous system activation triggers the development of heart failure. The transcription factor Y-box binding protein 1 (YB-1) can interact with transcription factors involved in cardiac hypertrophy and may thereby interfere with the hypertrophy growth process. Therefore, the question arises as to whether YB-1 influences cardiomyocyte hypertrophy and might thereby influence the development of heart failure. YB-1 expression is downregulated in human heart biopsies of patients with ischemic cardiomyopathy (n = 8), leading to heart failure. To study the impact of reduced YB-1 in cardiac cells, we performed small interfering RNA (siRNA) experiments in H9C2 cells as well as in adult cardiomyocytes (CMs) of rats. The specificity of YB-1 siRNA was analyzed by a miRNA-like off-target prediction assay identifying potential genes. Testing three high-scoring genes by transfecting cardiac cells with YB-1 siRNA did not result in downregulation of these genes in contrast to YB-1, whose downregulation increased hypertrophic growth. Hypertrophic growth was mediated by PI3K under PE stimulation, as well by downregulation with YB-1 siRNA. On the other hand, overexpression of YB-1 in CMs, caused by infection with an adenovirus encoding YB-1 (AdYB-1), prevented hypertrophic growth under α-adrenergic stimulation with phenylephrine (PE), but not under stimulation with growth differentiation factor 15 (GDF15; n = 10–16). An adenovirus encoding the green fluorescent protein (AdGFP) served as the control. YB-1 overexpression enhanced the mRNA expression of the Gq inhibitor regulator of G-protein signaling 2 (RGS2) under PE stimulation (n = 6), potentially explaining its inhibitory effect on PE-induced hypertrophic growth. This study shows that YB-1 protects cardiomyocytes against PE-induced hypertrophic growth. Like in human end-stage heart failure, YB-1 downregulation may cause the heart to lose its protection against hypertrophic stimuli and progress to heart failure. Therefore, the transcription factor YB-1 is a pivotal signaling molecule, providing perspectives for therapeutic approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic AgentsHeart FailureAdultHumansAnimalsRatsPhenylephrineMyocytes, CardiacRNA, Small InterferingAdenoviridaeCardiomegalyTranscription Factors

Stichwörter der Autor:innen

H9C2 cellsY-box binding protein 1cardiomyocyteshypertrophy

Substanzen

Adrenergic AgentsPhenylephrineRNA, Small InterferingTranscription Factors

Autor:innen und Institutionen

  • Institute of Physiology, Justus Liebig University, 35392 Giessen, Germany.
  • HCEMM-SU Cardiometabolic Immunology Research Group, 1094 Budapest, Hungary.
  • Cardiometabolic and MTA-SE System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1094 Budapest, Hungary.
  • Department of Heart Failure and Transplantology, Cardinal Stefan Wyszyński Institute of Cardiology, 04-628 Warszawa, Poland.
  • Pharmahungary Group, 6722 Szeged, Hungary.

ORCID-Profile: Zoltán V Varga, Bence Ágg, Bettina Benczik, Rainer Schulz, Gerhild Euler

Förderung

  • Innovation Fund of Hungary
  • European Union's Horizon 2020 research and innovation programme
  • the National Research, Development and Innovation Fund of Hungary
  • Ministry for Innovation and Technology in Hungary
  • European Union’s Horizon 2020 research and innovation program
  • National Research, Development, and Innovation Fund of Hungary
  • Thematic Excellence Programme
  • European Union

Zitieren

APA

Heger, J., Partsch, S., Harjung, C., Varga, Z. V., Baranyai, T., Weiß, J., Kremer, L., Locquet, F., Leszek, P., Ágg, B., Benczik, B., Ferdinandy, P., Schulz, R., & Euler, G. (2023). YB-1 Is a Novel Target for the Inhibition of α-Adrenergic-Induced Hypertrophy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25010401

Vancouver

Heger J, Partsch S, Harjung C, Varga ZV, Baranyai T, Weiß J, et al. YB-1 Is a Novel Target for the Inhibition of α-Adrenergic-Induced Hypertrophy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms25010401

BibTeX
@article{Heger2023,
  author = {Heger, Jacqueline and Partsch, Stefan and Harjung, Claudia and Varga, Zoltán V and Baranyai, Tamás and Weiß, Johannes and Kremer, Lea and Locquet, Fabian and Leszek, Przemyslaw and Ágg, Bence and Benczik, Bettina and Ferdinandy, Péter and Schulz, Rainer and Euler, Gerhild},
  title = {YB-1 Is a Novel Target for the Inhibition of α-Adrenergic-Induced Hypertrophy},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms25010401}
}
Kostenlos starten →